BE MOBILE 2: Bimekizumab in patients with active ankylosing spondylitis

In this MEDtalk, Professor in rheumatology Désirée Van Der Heijde, presents the 24-week results from the BE-MOBILE 2 study, suggesting a significant treatment efficacy in patients with active ankylosing spondylitis receiving bimekizumab (160 mg/4 week) versus placebo. Read more here; https://bpno.dk/artikler/bimekizumab-viser-positiv-effekt-over-hele-spektret-af-axial-spondyloarthritis/